New Double-Targeting drug enters first human test for severe lupus
NCT ID NCT07491900
Summary
This is a first-in-human study to test the safety and find the right dose of a new drug, HB2198, for people with moderate to severe lupus. About 30 participants with active lupus, including kidney involvement, will receive two doses of the drug and be followed for a year. The main goal is to see how safe the drug is and how it affects the body, while also checking for early signs it might help control lupus disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Investigational site
RECRUITINGBrisbane, Australia
Conditions
Explore the condition pages connected to this study.